-
DE
Estrogen receptor analysis is a diagnostic test that determines whether tumor cells carry estrogen receptors. The result plays a key role in guiding cancer treatment decisions.
Add as Preferred SourceEstrogen receptor analysis is a diagnostic test that determines whether tumor cells carry estrogen receptors. The result plays a key role in guiding cancer treatment decisions.
Estrogen receptor analysis (ER analysis) is a laboratory diagnostic procedure used to determine whether cancer cells – most commonly in breast cancer – carry estrogen receptors (ER) on their surface or within their nuclei. Estrogen receptors are protein molecules that bind the hormone estrogen. When a tumor is estrogen receptor-positive (ER+), it means that hormonal signaling can drive tumor growth. This information is critical for planning the most effective cancer treatment.
Estrogen receptor analysis is used in several clinical contexts:
Estrogen receptor analysis is typically performed on a tissue sample (biopsy) obtained during tumor surgery or a core needle biopsy. The tissue is processed in a pathology laboratory and examined using specialized techniques:
The most widely used method is immunohistochemistry. Labeled antibodies that specifically bind to estrogen receptors are applied to tissue sections. Under a microscope, a pathologist can determine how many tumor cells carry receptors and how strongly they are expressed. Results are typically reported as the percentage of positive cells and the staining intensity, often summarized using the Allred Score or H-Score.
In certain cases, molecular techniques such as RT-PCR (reverse transcriptase polymerase chain reaction) or gene expression profiling may be used to assess estrogen receptor status at the RNA level.
The results of estrogen receptor analysis are classified into two main categories:
The result of estrogen receptor analysis has direct implications for treatment:
It is important to note that estrogen receptor status can change during the course of the disease or following treatment. For this reason, a repeat biopsy and receptor analysis are often recommended at the time of relapse or when new metastases appear, in order to adapt the therapy accordingly.